$4.90
Value $406M
ASPN and BKNG stock compared: price, dividend, valuation and results, from SEC filings.
$4.90
Value $406M
$153.28
Value $114B
Aspen Aerogels (ASPN) has a market value of $406M and Booking (BKNG) $114B. Over the last year, with dividends, ASPN moved +60.1% and BKNG -19.5%. Dividend yield: ASPN none, BKNG 1.07%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ASPN$406M
BKNG$114B
BKNG is 281 times ASPN
Revenue, 12 months
ASPN$214M
BKNG$28.1B
BKNG is 131 times ASPN
Net income, 12 months
ASPN-$130M
BKNG$7.2B
Operating margin
ASPN-59.3%
BKNG32.8%
92.1 points apart
ROIC
ASPN-32.2%
BKNG66.1%
98.3 points apart
P/E
ASPN–
BKNG15.9
Dividend yield
ASPN0.0%
BKNG1.1%
1.1 points apart
5-year return
ASPN-92.1%
BKNG+65.8%
157.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ASPN-92.1%
BKNG+65.8%
| Period | ASPNWith dividends | BKNGWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +60.1%Price +60.1% | -19.5%Price -20.2% |
| 3 years since November 17, 2023 | -53.9%-22.8% a yearPrice -53.9% | +25.1%+7.8% a yearPrice +22.2% |
| 5 years since November 17, 2021 | -92.1%-39.8% a yearPrice -92.1% | +65.8%+10.6% a yearPrice +61.9% |
| 10 years since November 18, 2016 | +24.4%+2.2% a yearPrice +24.4% | +160.3%+10.0% a yearPrice +154.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ASPNAspen AerogelsBKNGBooking
| Price | $4.90 | $153.28 |
|---|---|---|
| Market value | $406M | $114B |
| Enterprise value (EV) | $337M | $118B |
| P/E | – | 15.9 |
| P/E, 5-year median | – | – |
| P/B | 2.2 | – |
| EV/EBIT | – | 12.8 |
| Free cash flow yield | 4.9% | 8.1% |
| Revenue, 12 months | $214M | $28.1B |
|---|---|---|
| Net income, 12 months | -$130M | $7.2B |
| Free cash flow, 12 months | $20M | $9.2B |
| Earnings per share, 12 months | -$1.58 | $9.26 |
| Revenue growth, year on year | -40.1% | 13.4% |
| Revenue growth a year, past | +22.0%over 5 years | +31.7%over 5 years |
| EPS growth a year, past | – | +158.3%over 5 years |
| Gross margin | 2.4% | – |
|---|---|---|
| Operating margin | -59.3% | 32.8% |
| Net margin | -60.8% | 25.5% |
| ROIC | -32.2% | 66.1% |
| ROE | -57.6% | – |
| Cash | $146M | $15.8B |
|---|---|---|
| Total debt | $99M | $20.6B |
| Net debt / EBITDA | – | 0.4 |
| Interest cover | – | 8.3× |
| Dividend yield | – | 1.1% |
|---|---|---|
| Dividend per share, 12 months | – | $1.64 |
| Dividend growth a year, past | – | – |
| Buyback yield | – | 5.7% |
| Shareholder yield | – | 6.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Booking ($114B) is about 280.9 times Aspen Aerogels ($406M), at today's prices.
Since November 18, 2016, ASPN's price moved +24.4% and BKNG's +154.2%. With dividends: ASPN +24.4% (+2.2% a year), BKNG +160.3% (+10.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Aspen Aerogels and 1.07% for Booking. Over the last twelve months they paid – and $1.64 per share.
Over the last twelve months, the net margin was -60.8% for Aspen Aerogels and 25.5% for Booking, and the operating margin -59.3% and 32.8%. Revenue was $214M and $28.1B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.